FDA Updates ALTUVIIIO Label with Full Pediatric Data in Hemophilia A
Announced by Sanofi on May 10, 2024, the updated FDA label is based on full results from the pivotal phase 3 XTEND-Kids study.
Thrombotic Adverse Events Frequent After Emicizumab for Hemophilia A
An analysis of an FDA adverse event database found thrombotic adverse events were more frequently reported with emicizumab than those of FVIII products.
Switch to Efmoroctocog Alfa May Lower Bleeding Events in Hemophilia A
Patients in France with hemophilia A who switched their FVIII replacement treatment trended towards fewer bleeding events and articular non-bleeding events requiring hospitalization.
Patients with Hemophilia A Without Inhibitors Have Low Physical Activity
Presented at ASH 2023, a new study demonstrated physical activity does not increase bleeding for patients with hemophilia A as patients with low physical activity still experienced frequent bleeding.
